KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Equity Average (2016 - 2025)

NovoCure (NVCR) has disclosed Equity Average for 11 consecutive years, with $340.9 million as the latest value for Q4 2025.

  • Quarterly Equity Average fell 5.43% to $340.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $340.9 million through Dec 2025, down 5.43% year-over-year, with the annual reading at $350.3 million for FY2025, 3.05% down from the prior year.
  • Equity Average hit $340.9 million in Q4 2025 for NovoCure, down from $345.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $443.5 million in Q3 2022 to a low of $340.9 million in Q4 2025.
  • Historically, Equity Average has averaged $393.2 million across 5 years, with a median of $394.7 million in 2021.
  • Biggest five-year swings in Equity Average: surged 84.6% in 2021 and later dropped 17.34% in 2024.
  • Year by year, Equity Average stood at $411.8 million in 2021, then rose by 7.64% to $443.3 million in 2022, then decreased by 14.71% to $378.1 million in 2023, then fell by 4.66% to $360.5 million in 2024, then decreased by 5.43% to $340.9 million in 2025.
  • Business Quant data shows Equity Average for NVCR at $340.9 million in Q4 2025, $345.4 million in Q3 2025, and $355.7 million in Q2 2025.